Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium (Pterygium)

• ClinicalTrials.gov Identifier: NCT03049852
• Recruitment Status: Completed
• First Posted: February 10, 2017
• Results First Posted: February 24, 2020
• Last Update Posted: February 24, 2020
• Sponsor: Cloudbreak Therapeutics, LLC
• Information provided by (Responsible Party): Cloudbreak Therapeutics, LLC

Study Description

Brief Summary:

Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24)

Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)

Condition or disease	Intervention/treatment	Phase
Pterygium	Drug: CBT-001 single dose; Drug: Vehicle; Drug: CBT-001 Multi-dose	Phase 2

Detailed Description:

Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24)

Objectives are to evaluate ocular safety and tolerability by biomicroscopy, ophthalmoscopy, intraocular pressure and visual acuity, and to assess general safety by physical exams, vital signs, clinical laboratory tests and adverse events reporting and to evaluate systemic CBT-001 exposure by Cmax, Tmax and an estimation of the area under the curve (AUC).

Three dose cohorts will be planned with a dose ascending strategy to guide dose concentrations (n=8 per Cohort x 3 cohorts = 24). Primary pterygium patients will be selected in this phase because the main goal is to assess the safety and tolerability of CBT-001 and primary pterygium patients are much easier to recruit. The ~8 primary pterygium patients from each Cohort will be administered a single ocular drug dose at Day 1 in the eye with primary pterygium; the unaffected eye will be dosed with vehicle. Examinations will be performed at both screening day (Day 0) and Day 1. Blood samples at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours post dose will be taken at Day 1 to assess systemic pharmacokinetics (PK). The data will be reviewed by Data Review Committee (DRC) to determine whether to initiate enrollment for the next Cohort.

Cohort 1 will begin at the lowest CBT-001 concentration of 0.02%, followed by an increasing dose to 0.05% for Cohort 2 and then to 0.2% for Cohort 3. If no safety issues are found at all doses, the highest dose of 0.2% will be used for the next phase study.

Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)

Objectives are to evaluate ocular and systemic safety of CBT-001 in primary or recurrent patients that have moderate to severe pterygium vascularity and to assess whether CBT-001 is efficacious in reducing pterygium vascularity and pterygium lesion growth. The dosing will be 4 weeks. The followup period will be 5 months.

Study Population Characteristics: Approximately 50 (30 primary pterygium and 20 recurrent) patients will be enrolled at up to 3 centers to have an estimated 40 patients complete the study based on an anticipated dropout rate of 20%. Although we have no evidence to suggest attrition due to Adverse Effects (AEs), the dropout rate is most conservative based on industry experience in comparable clinical studies. Patients will be randomized in a 1:1 treatment allocation to receive either CBT-001 0.2% or Vehicle.

Dosage/Dose regimen: One drop of the assigned study medication will be administered in the study eye TID for 4 weeks. The study eye is defined as the qualified eye (i.e., the eye meeting the inclusion criterion for primary or recurrent pterygium). If both eyes are qualified, then the eye with the more severe vascularity grade on the Pterygium Hyperemia Grading Scale at the baseline (Day 1) visit will be the study eye. If both eyes meet the criterion and have the same severity, the right eye will be the study eye. Patients with bilateral pterygium will administer study medication only in the study eye. The fellow eyes in all study subjects will be untreated.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 75 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium
• Actual Study Start Date: April 15, 2017
• Actual Primary Completion Date: April 30, 2018
• Actual Study Completion Date: April 30, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: CBT-001 Ophthalmic Solution Single dose; One drop in the study administered one time only for one day	Drug: CBT-001 single dose; One drop in the study administered one time
Placebo Comparator: Vehicle; One drop in the study administered three times daily (TID) for 4 weeks	Drug: Vehicle; One drop in the study administered three times daily (TID) for 4 weeks
Experimental: CBT-001 Ophthalmic Solution Multidose; One drop in the study administered three times daily (TID) for 4 weeks	Drug: CBT-001 Multi-dose; One drop in the study administered three times daily (TID) for 4 weeks

Outcome Measures

Primary Outcome Measures :

1. Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale [ Time Frame: Change from baseline at 4 weeks ]
   The primary efficacy variable is the change from baseline (Day 1) in severity grade of pterygium vascularity at Week 4. Pterygium vascularity intensity is based on color coordinates as measured by digital image analysis of pterygium photographs. The quantitative analysis of photographs using a 5-point Pterygium Hyperemia Grading Scale (0 = absent, 1 = trace, 2 = mild, 3 = moderate, 4 = severe) will be conducted at an independent image reading center.
2. Ocular and General Safety and Tolerability [ Time Frame: One day ]
   The ocular safety and tolerability are measured by biomicroscopy, ophthalmoscopy, intraocular pressure and visual acuity, and to assess general safety by physical exams, vital signs, clinical laboratory tests and adverse events reporting

Secondary Outcome Measures :

1. Corneal Pterygium Lesion Length Change From Baseline [ Time Frame: 4 weeks ]
   The Corneal Pterygium Lesion Length is measured from digital images of the eye by an independent image reading center.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale ≥ 3)

Exclusion Criteria:

• Active ocular disease, corneal abnormalities other than pterygium, active ocular infection, or any ocular pathology unrelated to pterygium in either eye that could affect the assessment of the pterygium
• History of ocular herpes disease in either eye
• Any ocular surgical procedure within the last 3 months
• Female patients who are pregnant, nursing, or planning a pregnancy during the study

Contacts and Locations

Locations

United States, California

Harvard Eye Associates

Laguna Beach, California, United States, 92651

Sponsors and Collaborators

Cloudbreak Therapeutics, LLC

Investigators

• Principal Investigator: John Hovanesian, M.D.; Harvard Eye Associates

  Study Documents (Full-Text)

Documents provided by Cloudbreak Therapeutics, LLC:

Study Protocol and Statistical Analysis Plan  [PDF] April 12, 2017

More Information

• Responsible Party: Cloudbreak Therapeutics, LLC
• ClinicalTrials.gov Identifier: NCT03049852
• Other Study ID Numbers: CBT-CS101
• First Posted: February 10, 2017
• Results First Posted: February 24, 2020
• Last Update Posted: February 24, 2020
• Last Verified: September 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Pterygium; Conjunctival Diseases; Eye Diseases